PIK3CB and cancer: In addition to optimising drug selectivity and dose to enhance efficacy and safety, the control of systemic metabolism by dietary manipulation is shown to be a highly effective strategy for improving safety and efficacy of PI3K inhibitors in preclinical cancer models [19].